Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

Why did the S&P 500 erase all 2025 losses? How will GOP tax bill affect Tesla and Musk? What caused UnitedHealth CEO to resign unexpectedly? How will NJ Transit strike impact commuters and businesses? Why did Coinbase shares soar after S&P inclusion? What are the implications of Nvidia’s Saudi AI deal? How are tariffs impacting Japanese automakers like Nissan and Honda? Why did Microsoft announce significant global workforce layoffs? How will Trump’s executive order affect U.S. drug prices?

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

benzinga.com/general/biotech/25/05/45393806/ten-year-data-from-roches-breast-cancer-trial-shows-perjeta-based-regimen-cuts-death-risk-by-17

Roche Holdings AG (OTC:RHHBY) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer.
After ten years, the risk of death was…

This story appeared on benzinga.com, 2025-05-13 21:37:09.